Reporter Staff
| This email address is being protected from spambots. You need JavaScript enabled to view it.
March 01, 2023
DECLARE Study
We are recruiting healthy men & women who are between 55-75 years of age AND have hypertension for the DECLARE Study.
The purpose of this research study is to examine the effects of 10 weeks of exercise on the brain. DEcreasing Cognitive Loss and Vascular Rarefaction with Exercise (DECLARE) is focused on the elucidation of exercise effects on brain health and the way by which exercise mitigates age-related growth factor deficiencies, hypertension and cognitive decline.
To participate in this research, you must:
– have high blood pressure
– be between 55-75 years of age
– be healthy (Ok to be on medication)
– not currently exercising
Please contact us at 205-996-5592 or use the following link to complete the 5 minute screening questionnaire: https://uab.co1.qualtrics.com/jfe/form/SV_6FigP3lOJYdvl9c
The purpose of this research study is to examine the effects of 10 weeks of exercise on the brain. DEcreasing Cognitive Loss and Vascular Rarefaction with Exercise (DECLARE) is focused on the elucidation of exercise effects on brain health and the way by which exercise mitigates age-related growth factor deficiencies, hypertension and cognitive decline.
To participate in this research, you must:
– have high blood pressure
– be between 55-75 years of age
– be healthy (Ok to be on medication)
– not currently exercising
Please contact us at 205-996-5592 or use the following link to complete the 5 minute screening questionnaire: https://uab.co1.qualtrics.com/jfe/form/SV_6FigP3lOJYdvl9c
Published in
Clinical Trials
February 27, 2023
My Health Rewards offers incentives for making healthy choices
This past year, more than 4,700 employees activated their My Health Rewards account, and more than 3,600 logged enough healthy behaviors to receive a payout of $50 or more. Activate your account and explore new ways to earn cash rewards.
Published in
Be Healthy
February 23, 2023
Adolescent study for depression
Are you between the ages of 11 and 19?
Are you feeling sad, down, or hopeless?
Are you feeling guilty, tense, or irritable?
If so, you may be eligible to participate in a study.
Compensation provided.
For more information, please call Brennan Wink at 205-975-4208 or send an email to Brennanwink@uabmc.edu.
Published in
Clinical Trials
February 22, 2023
Lung Health Cohort
One Breath Matters.
Are you or someone you care about age 25-35 and interested in lung health? Join the landmark Lung Health Cohort Research Study to improve the health of future generations.
The pioneering NIH-funded study will follow 4,000 young, healthy adults to paint a clearer picture of lung health and the factors involved in predicting and preventing lung disease.
To learn more, visit: Lung.org/lung-study
Are you or someone you care about age 25-35 and interested in lung health? Join the landmark Lung Health Cohort Research Study to improve the health of future generations.
The pioneering NIH-funded study will follow 4,000 young, healthy adults to paint a clearer picture of lung health and the factors involved in predicting and preventing lung disease.
To learn more, visit: Lung.org/lung-study
Published in
Clinical Trials
February 09, 2023
BabyCOVE Study: Evaluates the COVID-19 vaccine in healthy infants aged 12 weeks to less than 6 months old.
Your baby will have 2 injections, which will be 8 weeks apart. You will be asked to return to the study site with your baby up to 7 times over the course of 15 months. Your baby will be closely monitored by the study team if any symptoms of COVID-19 are reported at any time throughout their participation. Nasal swabs and blood draws will be required at 3-4 of the study site visits. Compensation for participation is available. To learn more, visit BabyCOVEStudy.com or contact the UAB study team: 205-638-2629 or mlpurser@uabmc.edu
Published in
Clinical Trials
The University of Alabama at Birmingham (UAB), in collaboration with Novo Nordisk, is conducting a 3-year research study to see if CagriSema, an investigational weekly medicine being studied for the treatment of obesity is also safe for the heart and blood vessels.
We are doing this study to see if CagriSema (Cagrilintide/semaglutide), a new medicine intended for the treatment of obesity, is safe for use in people living with obesity and cardiovascular disease. The study will also include some people with type 2 diabetes and/or chronic kidney disease.
You may qualify to participate if::
Want to know more about the REDEFINE 3 study?
Call the study team at (205) 996-4015 or via email ccnrn@uab.edu
We are doing this study to see if CagriSema (Cagrilintide/semaglutide), a new medicine intended for the treatment of obesity, is safe for use in people living with obesity and cardiovascular disease. The study will also include some people with type 2 diabetes and/or chronic kidney disease.
You may qualify to participate if::
- You have had a stroke, a heart attack (myocardial infarction), or have poor circulation (peripheral
- arterial disease)
- You are 55 years of age or older
- You are living with obesity (BMI ≥ 30 kg/m2 )
- You can have type 2 diabetes and/or chronic kidney disease
- You are able to attend regular clinic visits and receive phone calls over
- a period of 3 years
Want to know more about the REDEFINE 3 study?
Call the study team at (205) 996-4015 or via email ccnrn@uab.edu
Published in
Clinical Trials
February 03, 2023
3 chosen as UAB VIPs for fourth-quarter 2022
Tatyana Gavrikova, Sherry Polhill and Aparna Tamhane are the fourth-quarter 2022 honorees of the UAB Shared Values in Action Program, which honors those whose work exemplifies and embodies Forging the Future's shared values. Nominations for first-quarter 2023 honorees are open through Feb. 28.
Published in
Awards & Honors
January 24, 2023
SAVITRI Study for Depression
If you’re being treated for MDD and your current antidepressant medication(s) is not working, the SAVITRI Study might interest you. The SAVITRI Study is researching a potential MDD therapy to improve symptoms of depression, and you may be able to participate. This research study is now enrolling adults diagnosed with MDD. Those who qualify will receive the investigational medication (or placebo), study-specific medical exams, and study-specific laboratory tests at no cost. Participants in the SAVITRI Study must: be 18 to 65 years of age; have a clinical diagnosis of MDD; be currently on antidepressant medication(s); have had inadequate response to up to 5 oral antidepressant medications; and fulfill other eligibility criteria. For more information, please call (205) 996-5987 or email lalexander@uabmc.edu. Please mention SAVITRI in your message.
Published in
Clinical Trials
January 24, 2023
Alzheimer’s Dementia and Agitation Clinical Study
Do you have a loved one with agitation associated with Alzheimer’s dementia? Is their agitation becoming overwhelming? Examples of some easily identifiable agitated behaviors are: restlessness, screaming, shouting, throwing things, resistiveness, constant unwarranted requests for attention or help, pacing/aimless wandering, kicking, hitting others or self, pushing people, hurting self or others, tearing things or destroying property. In this study, researchers want to find out if an investigational drug called AVP-786 is safe and effective (useful) in managing agitation in adults with Alzheimer’s dementia, when compared to a placebo. If you are a caregiver for a person with Alzheimer’s disease, please call (205) 996-5987 or email lalexander@uabmc.edu for more information.
Published in
Clinical Trials
January 19, 2023
Are you struggling to find a treatment for depression that works?
The RECOVER study was designed in partnership with many of the nation’s top experts in treatment-resistant depression, and approved by Medicare, to provide additional evidence of the benefit of VNS Therapy. If the results confirm previous studies, Medicare and other insurers may start to cover it.
People who participate in RECOVER will receive VNS Therapy and all study-related care at no cost to them.
To join the RECOVER study, you must be 18 years or
older and:
1. Currently depressed
2. Have depression, or bipolar depression, that has lasted for at least two years or recurred several times
3. Have tried at least four types of antidepressant treatments and not found them helpful
4. Have Medicare Insurance
People who participate in RECOVER will receive VNS Therapy and all study-related care at no cost to them.
To join the RECOVER study, you must be 18 years or
older and:
1. Currently depressed
2. Have depression, or bipolar depression, that has lasted for at least two years or recurred several times
3. Have tried at least four types of antidepressant treatments and not found them helpful
4. Have Medicare Insurance
Published in
Clinical Trials
